FGF23, Hypophosphatemia, and Emerging Treatments

by Erik A Imel, Andrew Biggin, Aaron Schindeler, Craig F Munns
Published 2019-08-01

Sarcopenia, frailty and cachexia patients detected in a multisystem electronic health record database

by Ranjani N. Moorthi, Ziyue Liu, Sarah A. El-Azab, Lauren R. Lembcke, Matthew R. Miller, Andrea A. Broyles, Erik A. Imel
Published 2020-07-01

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

by Mary D. Ruppe, Xiaoping Zhang, Erik A. Imel, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey S. Humphrey, Francis H. Glorieux, Anthony A. Portale, Karl Insogna, Munro Peacock, Thomas O. Carpenter
Published 2016-12-01

Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial

by Peter Kamenický, Anthony A. Portale, Tom Carpenter, Karine Briot, Erik A. Imel, Thomas Weber, Pisit Pitukcheewanont, Hae Il Cheong, Suzanne Jan de Beur, Yasuo Imanishi, Nobuaki Ito, Robin Lachmann, Hiroyuki Tanaka, Farzana Perwad, Lin Zhang, Alison Skrinar, Linda Rees, Karl L. Insogna
Published 2020-10-01